According to CNIO, among the various kinds of cancer, pancreatic cancer remains one of the deadliest and is a widely known ...
Explore groundbreaking research on pancreatic cancer treatment that shows promise in inducing complete tumour regression.
Scientists achieved pancreatic cancer tumour disappearance in mice using a triple combination therapy, paving the way for ...
Atebimetinib is an investigational oral deep cyclic inhibitor that targets MEK in the MAPK pathway, which is activated in many solid tumors including pancreatic cancer. Its mechanism of action is ...
The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal ...
A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Combination therapies represent a promising frontier in cancer treatment, addressing the critical need to enhance efficacy ...
Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results